Skip to content
PIL Logo

Estradot 25, 37.5, 50, 75 and 100 micrograms/24 hours, transdermal patches

Last Updated on eMC 01-Jun-2016 View document  | Novartis Pharmaceuticals UK Ltd Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 01-Jun-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 14-Mar-2016 and displayed until 01-Jun-2016

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 5 - how to store
  • Change to section 6 - date of revision

Updated on 21-Apr-2015 and displayed until 14-Mar-2016

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 13-Jun-2014 and displayed until 21-Apr-2015

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 14-May-2012 and displayed until 13-Jun-2014

Reasons for adding or updating:

  • Change due to harmonisation of PIL.
  • Change to drug interactions

Updated on 21-Jun-2011 and displayed until 14-May-2012

Reasons for adding or updating:

  • Change to date of revision
  • Unknown

Updated on 25-Mar-2010 and displayed until 21-Jun-2011

Reasons for adding or updating:

  • Introduction of new pack/pack size

Updated on 25-Sep-2009 and displayed until 25-Mar-2010

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 01-May-2009 and displayed until 25-Sep-2009

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 18-Mar-2005 and displayed until 01-May-2009

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Novartis Pharmaceuticals UK Ltd

Company image
Address

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR

E-mail
Medical Information e-mail
Telephone

+44 (0)1276 692 255

Medical Information Direct Line

+44 (0)1276 698 370

Customer Care direct line

+44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

estradiol hemihydrate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue